Experimental risk assessment of bovine viral diarrhea virus transmission via in vitro embryo production using somatic cell nucleus transfer.
The objective of this study was to perform a comprehensive risk assessment on infectious disease transmission in the system of in vitro embryo production via somatic cell nucleus transfer (SCNT) technology using bovine viral diarrhea virus (BVDV) as a model. The risks of BVDV transmission in each step of the SCNT embryo production procedure, from donor cells to preimplantation SCNT embryo culture, were carefully examined using a sensitive real-time polymerase chain reaction assay. The identified primary source of BVDV transmission in SCNT embryo production was donor cell infection, most likely caused by contaminated fetal bovine serum in the culture medium. The risk of disease transmission through contaminated oocytes from an abattoir was relatively low, and it can be greatly minimized by cumulus cell removal and adequate oocyte washing procedures. Of the 200 cumulus-oocyte complexes (COCs) and more than 1500 cumulus cell-free oocyte (CFO) samples collected from multiple sources over a course of 7 months, only 2.5% of the COCs were BVDV positive, and all of the CFOs (100%) were BVDV negative. To evaluate the risk of BVDV introduction during in vitro SCNT embryo culture, 324 SCNT embryos were produced from 18 different cell lines using oocytes from 26 different batches collected over a course of 9 months. The embryos were cultured in vitro for 7 days and then tested for BVDV. All of the 324 SCNT embryos (100%) were negative, indicating that the embryo culture system is virtually risk-free for BVDV transmission. Based on these results, a standard operational protocol (SOP) for SCNT embryo production was proposed to greatly minimize the risk of BVDV transmission through the SCNT embryo production system. This SOP could be a starting point to produce a SCNT system that is virtually risk-free for disease transmission in general.
Viagen, Inc., 12357-A Riata Trace Parkway, Suite 100, Austin, TX 78727, USA. Keqin.gregg@viagen.com
K
K
Gregg
S H
SH
Chen
S
S
Sadeghieh
T
T
Guerra
T
T
Xiang
J
J
Meredith
I
I
Polejaeva
D000818:Animals; D001755:Blastocyst / Q000821:virology; D001912:Bovine Virus Diarrhea-Mucosal Disease / Q000635:transmission*; D002417:Cattle / Q000196:embryology / Q000821:virology*; D002460:Cell Line; D019976:Cloning, Organism / Q000662:veterinary*; D003470:Culture Media; D001908:Diarrhea Viruses, Bovine Viral / Q000235:genetics / Q000302:isolation & purification*; D046149:Embryo Culture Techniques / Q000662:veterinary; D005260:Female; D005312:Fetal Blood / Q000821:virology; D005347:Fibroblasts / Q000648:ultrastructure / Q000821:virology; D053652:Nuclear Transfer Techniques / Q000662:veterinary*; D009865:Oocytes / Q000821:virology; D016133:Polymerase Chain Reaction; D012367:RNA, Viral / Q000737:chemistry; D018570:Risk Assessment; D016415:Sequence Alignment
D003470:Culture Media; D012367:RNA, Viral